Walter S. Woltosz, a director and significant shareholder of Simulations Plus , Inc. (NASDAQ:SLP), recently sold 20,000 shares of the company's common stock. The company, currently valued at $628.5 million, maintains a GOOD financial health score according to InvestingPro analysis. The shares were sold at prices ranging from $31.47 to $32.04, totaling approximately $635,200. Following this transaction, Woltosz holds 3,442,584 shares in the company. The sale was executed automatically as part of a pre-arranged trading plan under Rule 10b5-1. Notably, analysts maintain a bullish outlook with price targets ranging from $39 to $65, suggesting potential upside. For deeper insights into SLP's valuation and 12+ additional ProTips, consider exploring the comprehensive research available on InvestingPro.
In other recent news, Simulations Plus, Inc. has secured a grant from the U.S. Food and Drug Administration for a collaboration with the University of Strathclyde and InnoGI Technologies, aimed at advancing drug testing technology. The project is expected to improve the understanding and prediction of amorphous solid dispersion formulations. Simulations Plus has also reported robust financial results for fiscal year 2024, with total revenue up by 18% to $70 million and a fourth-quarter revenue rise of 19% to $18.7 million. However, the company's fourth-quarter revenue fell short of the $19.7 million expected by BTIG and the consensus estimate. Despite this, Simulations Plus issued financial guidance for fiscal year 2025, including revenue projections aligning with initial estimates and an adjusted earnings per share forecast between $1.07 and $1.20. BTIG has adjusted the financial outlook for Simulations Plus, reducing the price target to $50.00 from the previous $60.00 while still holding a Buy rating on the stock. These recent developments reflect the company's ongoing financial performance and market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.